Cytosorbents vs Orchestra BioMed
CTSO and OBIO side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CTSO and OBIO compare
Cytosorbents and Orchestra BioMed are about the same size, with market caps of $336M and $361M.
Orchestra BioMed grew revenue faster over the last twelve months (1007% versus 3.1% for Cytosorbents).
Cytosorbents keeps more of each dollar of sales as profit, with a net margin of −48.9% compared with −183% at Orchestra BioMed.
Orchestra BioMed scores higher on the StockData Score (9 against 2 for Cytosorbents), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CTSO | OBIO |
|---|---|---|
| Size and price | ||
| Market cap | $336M | $361M |
| Share price | $5.34 | $6.01 |
| Change, 1 year | −63.0% | 59.0% |
| Change, 5 years | −94.9% | −39.0% |
| Beta (5Y) | 0.96 | 0.80 |
| Employees | 129 | 86 |
| StockData Score | ||
| Total score | 2 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 1 |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 9.0× (better) | 11.6× |
| FCF yield | −2.8% (better) | −17.8% |
| Growth | ||
| Revenue growth (TTM) | 3.1% | 1007% (better) |
| Revenue growth, 5Y average | −2.0% | – |
| Profitability | ||
| Gross margin | 71.6% | 99.6% (better) |
| Operating margin | −34.7% (better) | −195% |
| Net margin | −48.9% (better) | −183% |
| FCF margin | −25.0% (better) | −206% |
| Return on equity | −336% | – |
| Return on invested capital | −73.4% | – |
| Financial health | ||
| Current ratio | 0.66 | 7.25 (better) |
| Altman Z-score | −7.07 | −3.68 (better) |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 1.3% | 46.1% |
| Held by insiders | 2.5% | 56.6% |
| Insider net buying, 12 months | $269K (better) | $50.4K |
| Short interest, % of float | 0.22% | 10.5% |
Go deeper
- CTSO stock overview
- CTSO income statement
- CTSO valuation and score
- OBIO stock overview
- OBIO income statement
- OBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.